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We agree with the authors that insufficient evidence is provided to advocate rhTSH for the preparation to radioiodine therapy in case of metastatic disease, but our recommendations clearly state that we advocate rhTSH for ablation and not therapy. rhTSH improves the quality of life avoiding hypothyroidism, reduces the cost for the society in terms of labor-days lost and reduces the radiation exposure to the whole body [2] .
Several lines of evidence demonstrate that there is no difference in fixed doses or personalized dosimetry regarding patients' outcome. This is true for metastatic disease, but even more for thyroid ablation. Regarding the EU Directive, whose expert panel probably did not include any expert in thyroid cancer, it is not a relevant issue and does not deserve any comment.
It is true that no prospective study on the effect of low iodine diet is available. However, in a country like Italy with moderate iodine deficiency, one study has clearly shown that in this context iodine status or the use of iodized salt has no influence on the outcome of thyroid ablation [3] .
Finally, regarding the statement on the multidisciplinary team, the authors are wrong. The recommendations were developed by a multidisciplinary team including two nuclear medicine physicians.
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Dear Editor,
We read with interest the letter from Sollini M et al. in this issue of the journal [1] . Their comments are of crucial importance and we thank them for this.
Basically, the authors raise several points that deserve our reply.
As stated by the authors, ablative RAI is a nuclear medicine treatment crucial in the management of DTC, since it may reduce long-term morbidity and possibly, mortality. However, it is more and more evident that this statement does not apply to patients in the low risk category. Nowadays, more than 80 % of differentiated thyroid cancer is represented by small thyroid cancer limited to the thyroid gland, in which the rate of recurrence is lower than 2-3 % and mortality is almost absent. In these tumors, radioiodine ablation does not add any beneficial effect both in the shortand in the long-term follow-up. Even in patients in the intermediate risk category, evidences of clear benefit are lacking, and, consequently the use of low radioiodine activity is advocated by the most authoritative groups and a personalized approach should be preferred to the general concept of "the same therapy for any patient". Of course, this
